SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis

被引：0
作者：
Tsvetelina Velikova
Tsvetoslav Georgiev
机构：
[1] University Hospital “Lozenetz”,Department of Clinical Immunology, Medical Faculty
[2] Sofia University St. Kliment Ohridski,First Department of Internal Medicine, Faculty of Medicine
[3] Medical University-Varna,Clinic of Rheumatology
[4] University Hospital “St. Marina”,undefined
来源：
Rheumatology International | 2021年 / 41卷
关键词：
COVID-19; SARS-CoV-2; COVID-19 vaccines; Autoimmune diseases; Messenger RNA; Vaccination; Rheumatic diseases;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Coronavirus disease 2019 (COVID-19) pandemic has become challenging even for the most durable healthcare systems. It seems that vaccination, one of the most effective public-health interventions, presents a ray of hope to end the pandemic by achieving herd immunity. In this review, we aimed to cover aspects of the current knowledge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and vaccine candidates in the light of autoimmune inflammatory diseases (AIIDs) and to analyze their potential in terms of safety and effectiveness in patients with AIIDs. Therefore, a focused narrative review was carried out to predict the possible implications of different types of SARS-CoV-2 vaccines which confer distinct immune mechanisms to establish immune response and protection against COVID-19: whole virus (inactivated or weakened), viral vector (replicating and non-replicating), nucleic acid (RNA, DNA), and protein-based (protein subunit, virus-like particle). Still, there is uncertainty among patients with AIIDs and clinicians about the effectiveness and safety of the new vaccines. There are a variety of approaches towards building a protective immunity against SARS-CoV-2. Only high-quality clinical trials would clarify the underlying immunological mechanisms of the newly implemented vaccines/adjuvants in patients living with AIIDs.
引用
收藏
页码：509 / 518
页数：9
相关论文
共 235 条
  • [11] Desvars-Larrive A(2018)Comorbidities in rheumatic arthritis Reumatologia 56 228-161
  • [12] Loreto V(2020)Incidence of COVID-19 in patients with rheumatic disease: is prior health education more important than shielding advice during the pandemic? Clin Rheumatol 11 1-52
  • [13] Pinior B(2020)COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases Clin Exp Immunol 202 149-256
  • [14] Thurner S(2020)2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases Ann Rheum Dis 79 39-258
  • [15] Klimek P(2021)Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic Rheumatol Int 41 243-652
  • [16] Gasparyan AY(2009)Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol 9 246-3886
  • [17] Misra DP(2009)Vaccines and autoimmunity Nat Rev Rheumatol 5 648-69
  • [18] Yessirkepov M(2005)Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines Vaccine 23 3876-311
  • [19] Zimba O(2010)Could autoimmunity be induced by vaccination? Int Rev Immunol 29 47-290
  • [20] Georgiev T(2017)Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? EPMA J 8 295-562
12345678910